BIOCON

BSE: 532523 04 Dec 2025

Healthcare

₹ 388.25 ▼ -5.34%

Biocon Ltd. specializes in Pharmaceuticals within the Healthcare sector.

BIOCON

BSE: 532523 04 Dec 2025

Healthcare

₹ 388.25 ▼ -5.34%

Biocon Ltd. specializes in Pharmaceuticals within the Healthcare sector.

High

410.3

Low

410

Open

410

Prev Close

410.15

Market Cap

51907.61 Cr

BIOCON - Share Price & Details

Market Cap

₹ 51,907.61

WAP

393.01

Turnover

18.90(Cr.)

TTQ

4.81(Lakh)

2 Week Avg Qty

1.49(Lakh)

Circuit Limit

4,81,003.00/349.45

Stock P/E

125.0

Book Value

₹180.0

Dividend Yield

0.15

ROCE

6.25

ROE / PB

6.13 / 4.77

Face Value

5.00

PEG Ratio

11.9

EVEBITDA

₹17.3

Debt

18,362

CMP / FCF

47.0

Debt to equity

₹0.85

NP Ann

1,429

High price all time

488.0

Piotroski score

₹6.0

Graham Number

114.0

No. Eq. Shares

134.0

Net CF

₹2,004

Net profit

657

Price to book value

1.88

Interest Coverage

₹1.82

Low price all time

14.2

Industry PE

33.0

Reserves

₹21,044

Free Cash Flow

₹1,718

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
14 Nov 2025	ICICI Securities	Sell	₹411	₹320	-24%	moneycontrol	View
12 Nov 2025	Motilal Oswal	Buy	₹406.35	₹480	16.7%	moneycontrol	View
09 Aug 2025	ICICI Securities	Sell	₹343.35	₹270	-24.8%	moneycontrol	View
08 Aug 2025	Motilal Oswal	Buy	₹343.35	₹410	19.8%	moneycontrol	View
13 Jan 2025	Motilal Oswal	Buy	₹364.8	₹430	17.7%	moneycontrol	View
20 Nov 2024	Geojit Financial Services	Buy	₹327.1	₹376	0%	moneycontrol	View
12 Nov 2024	Sharekhan	Buy	₹347.65	₹400	6.3%	moneycontrol	View
04 Jul 2024	Sharekhan	Buy	₹361.1	₹400	6.9%	moneycontrol	View
17 Jan 2024	Sharekhan	Buy	₹279.8	₹332	-11.1%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.95	-1.93	NA	-7.86	0
BIOCON LTD.	43,885.00	1,328.00	42,955.00	0.65	45,310	125.0
GLAXOSMITHKLINE PHARMACEUTICAL	10,135.10	2,574.90	9,799.40	15.20	45272	47.8
Laurus Labs Limited	15,950.50	2,156.70	15,666.00	3.99	44930	88.3

Peer Comparison Chart

About BIOCON

Biocon Ltd., with Security Code 532523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Bridging Continents, Saving Lives: Biocon First Manufacturing Facility in The U.S.

(22 Sep 2025)

In a proud moment for Indian innovation as well as Healthcare worldwide, Biocon Limited has officially inaugurated its first manufacturing...

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

(22 Sep 2025)

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada.

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

(22 Sep 2025)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Biocon Limited (NSE:BIOCON) as an...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	562.8	532.6	510.6	525.4	562.8	643.8	537.1	583.3
Expenses	491.5	480.4	465.7	487.8	531.5	581.8	516.5	530.4
Operating Profit	71.3	52.2	44.9	37.6	31.3	62.0	20.6	52.9
OPM %	12.67%	9.8%	8.79%	7.16%	5.56%	9.63%	3.84%	9.07%
Other Income	48.5	38.9	41.9	73.5	671.7	62.7	61.3	133.8
Interest	56.0	39.5	55.2	59.7	65.3	56.7	56.2	67.2
Depreciation	30.9	29.8	30.5	30.5	33.8	33.0	33.3	33.8
Profit before tax	32.9	21.8	1.1	20.9	-3.6	35.0	-7.6	85.7
Tax %	-27.1%	-35.8%	18.2%	84.7%	-3.3%	-39.4%	-9.2%	17.3%
Net Profit	24.0	14.0	0.9	3.2	584.0	21.2	-8.3	70.9
EPS in Rs	0.2	0.12	0.01	0.03	4.87	0	-0.07	0.55

Metrics	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025
Sales	3,462.3	3,953.7	3,917.1	3,432.9	3,590.4	3,821.4	4,417.0	4,295.5
Expenses	2,744.9	3,051.0	3,003.9	2,812.5	2,905.0	3,069.6	3,338.8	3,460.1
Operating Profit	717.4	902.7	913.2	620.4	685.4	751.8	1,078.2	835.4
OPM %	20.72%	22.83%	23.31%	18.07%	19.09%	19.67%	24.41%	19.45%
Other Income	133.9	586.7	39.8	1,166.5	58.5	52.9	57.3	81.1
Interest	247.7	266.7	227.0	236.0	225.6	223.4	212.4	272.2
Depreciation	389.3	414.5	407.0	405.4	419.9	425.4	436.3	473.0
Profit before tax	238.3	787.0	327.8	1,113.5	72.4	137.8	466.4	183.2
Tax %	-17.4%	-6.6%	-29.9%	-24.8%	-72.5%	48%	-5.6%	-22.5%
Net Profit	172.7	753.3	222.9	861.8	27.1	81.1	459.4	132.8
EPS in Rs	1.05	5.51	1.13	5.51	0.13	0.21	0	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	0%
5 Years:	2%
3 Years:	9%
TTM:	5%

Compounded Profit Growth
10 Years:	-18%
5 Years:	-31%
3 Years:	-16%
TTM:	-54%

Stock Price CAGR
10 Years:	16%
5 Years:	-1%
3 Years:	0%
1 Year:	5%

Compounded Sales Growth
10 Years:	17%
5 Years:	19%
3 Years:	23%
TTM:	3%

Compounded Profit Growth
10 Years:	9%
5 Years:	7%
3 Years:	10%
TTM:	-3%

Stock Price CAGR
10 Years:	16%
5 Years:	-1%
3 Years:	0%
1 Year:	5%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

BIOCON

BIOCON

BIOCON - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About BIOCON

Order Book

Latest News

Bridging Continents, Saving Lives: Biocon First Manufacturing Facility in The U.S.

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Biocon unit gets public funding for retinal disorder medication

Biocon arm's retinal disorder medication Yesafili gets public funding in Canada

Biocon arm gets Ontario listing for retinal drug; check details

Biocon Shares Gain 3% on Gaining Two USFDA Approvals

Stocks To Watch: Dr Reddys Labs, Mobikwik, Kfin Tech, PC Jeweller, Biocon

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars to treat osteoporosis and bone...

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases – Company Announcement - FT.com

Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs

‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push

Biocon inaugurates first US manufacturing facility in New Jersey

Biocon inaugurates first manufacturing facility in US

Biocon Opens First U.S. Manufacturing Facility in New Jersey

Biocon shares in focus as it opens manufacturing facility in New Jersey

Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection

Biocon Ltd spurts 1.42%

Biocon Shares Trade 1% Higher as Arm Secures USFDA Approval

Biocon unit gets USFDA approval for diabetes drug Sitagliptin

Biocon unit gets US FDA tentative nod for diabetes drug Sitagliptin

FDA gives Biocon unit tentative OK for stitaglipin tablets

Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin

Biocon Q1 Profit Rises 7 Per Cent To Rs 2.9 Billion

Biocon Q1 Results | Net profit tanks 95% to ₹31 crore, misses estimates

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Biocon Faces Market Volatility Amid Broader Sector Declines and Bearish Trends

Biocon Biologics eyes global expansion with focus on insulin and GLP-1 therapies

Biocon Biologics posts strong Q1 growth as North America, Europe deliver | Company Business News

Biocon Q1 Net Profit Dips 95% to ₹31.4 Crore

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Biocon’s profitability to improve as structured equity exits ease interest burden: Kiran Mazumdar-Shaw

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%

Biocon Q1 net profit falls 95% to Rs 31 crore

Biocon Ltd slips for fifth straight session

BIOCON Stock Price and Chart — NSE:BIOCON

Biocon Surges 3.5% After FDA Nod for Kirsty™ Insulin Biosimilar

Biocon appoints Ekta Agarwal as Interim Company Secretary, Compliance Officer

Macro Trends and Their Impact on Biocon Limited (BIOCON) - Powerful growth strategies

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications

Biocon unit launches Entracept biosimilar in Australia, expands global footprint

Biocon Biologics names Deepali Naair as Global Head Brand Corp Comm

Biocon Biologics launches Nepexto in Australia

Biocon Limited (532523) Signs Major Deal - Market-crushing profits

Biocon Limited (532523) Expands into New Market - Free Investment Community

Biocon Ltd. Achieves 52-Week High Amid Strong Operational Performance and Market Confidence

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Biocon Biologics gets Health Canada approval for its AMD biosimilar Yesafili

Biocon Biologics to launch Eylea biosimilar Yesafili in Canada next month

Upcoming Dividend: Biocon, Escorts Kubota, Nestle, Welspun, Other Shares To Trade Ex-Date Next Week

11 of 18 stocks trade above QIP issue price; Rs 25,600 crore raised via QIPs in 2025

Biocon Biologics Receives Health Canada Approval for

Biocon Acquires Biocon Biologics Debentures

Biocon Biologics receives Health Canada approval for Yesafili

Stocks To Watch Today: HCLTech, HDFC Bank, L&T Finance, Cipla, New India Assurance, Biocon

After a $3.3 bn acquisition, is it finally time to look at Biocon?

Stock To Buy: Biocon, LIC, Tech Mahindra, Valor Estate, Voltas

Biocon Ltd soars 3.52%, Gains for third straight session

Biocon's Stock Rebounds Amidst Broader Market Optimism and Small-Cap Gains

Biocon Gains 1% After India Nod for Diabetes Drug Liraglutide

Biocon gets approval for diabetes drug Liraglutide in India

Biocon shares in focus after CDSCO nod for diabetes drug Liraglutide

Biocon Biologics receives MHRA approval for YESINTEK

Biocon Biologics receives MHRA approval for Yesintek

Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK

Biocon Shares Gain 1% as Subsidiary Secures Approval from UK MHRA

Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek

Biocon gets six-month extension on insulin supply contract In Malaysia